Figure 1.

ADV treatment showed antitumor activity and effectively increased tumor immune infiltration

(A) Experimental schematic of mice from Figures 1B–1M: 4T1 tumor-bearing wild-type (WT) mice were administered ADV or vehicle control (PBS) starting on day 10 when the tumor volume reached approximately 50–100 mm³. Tumor-infiltrating leukocytes (TILs) from the tumor and spleen were assessed by flow cytometry (day 19, day 24, day 35; n = 6 biological replicates); s.c., subcutaneous; i.t., intra-tumoral.

(B–D) 4T1-tumor-bearing WT mice were administered ADV or vehicle control (PBS) starting on day 10 when the tumor reached approximately 50–100 mm³ in volume (n = 10 biological replicates). (B) Tumor growth and individual tumor growth. (C) Body weight. (D) Survival.

(E–L) Percentages (top) and total cells normalized to g (gram) tumor tissue (bottom) of TILs. (E) CD3⁺CD4⁺ T cells, (F) CD3⁺CD8⁺ T cells, (G) CD11b⁺F4/80⁺ macrophages, (H) CD3⁻CD49b⁺ NK cells, (I) CD11c⁺CD86⁺ DCs, (J) CD25⁺Foxp3⁺ Tregs, (K) “M1-like” macrophages, (L) “M2-like” macrophages within the TME of mice (n = 6 biological replicates).

(M) Percentages (top) and total cells normalized to g tumor tissue (bottom) of CD4⁺ T cells (left) and CD8⁺ T cells (right) within the spleen of mice (n = 6 biological replicates). The data are shown as the means ± SD. NS, no significant difference; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.